CTRI/2024/02/062644
Not yet recruiting
未知
Prospective, Interventional, Proof-of-Science, Randomised, Evaluator-Blinded, In-Use Safety and Efficacy Study of Two Moisturising Creams in Wound-Healing. - NI
S H Kelkar and Company Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- S H Kelkar and Company Limited
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The subject is aged between 18 and 55 years (both inclusive) at the time of informed consent.
- •2\. The subject is a non\-pregnant, non\-lactating healthy adult female.
- •3\. No previous history of adverse skin conditions, and not under any medication likely to interfere with the results.
- •4\. The subject has a self\-reported negative urine pregnancy test.
- •5\. The subject is in a good general health as determined from recent medical history.
- •6\. The subject has willingness and ability to adhere to study directions, and agrees not to use any other skin creams, lotions, serums, etc. at the application sites, except for the specified test products, and return for all specified visits.
- •7\. The subject possesses the ability to comprehend and provide written informed consent for participation in the study.
Exclusion Criteria
- •1\. The subject is currently pregnant or lactating or is planning to become pregnant during the study period.
- •2\. The subject has a history of allergies or specific allergic reactions upon using dermatological or cosmetic products.
- •3\. The subject is currently enrolled in an active investigational study or has participated in an investigational study within 30 days prior to enrolment.
- •4\. The subject suffers from any active clinically significant disease or any condition that according to the discretion of the investigator warrants exclusion from the study.
- •5\. The subject is taking or has taken a medication which, in the judgement of the Investigator, makes the subject ineligible or places the subject at undue risk.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Effects and Implementation of the ACT Program in CearáRBR-5gbhw5wFaculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Completed
Not Applicable
A clinical study to assess the safety and effectiveness of different dosages of the same collagen peptide and different collagen peptide-containing test treatments in adult human subjectsHealth Condition 1: L709- Acne, unspecifiedHealth Condition 2: M170- Bilateral primary osteoarthritis of kneeHealth Condition 3: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhereHealth Condition 4: M256- Stiffness of joint, not elsewhereclassifiedCTRI/2022/11/047149Collagen Lifesciences Private Limited264
Completed
Not Applicable
A Clinical Study to evaluate the effectiveness of Jolly Tulsi 51 drops for Boosting Immune system and Detoxification in healthy subjects.CTRI/2018/02/012126Jolly Health Care30
Recruiting
Phase 3
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumabdecrease of the left ventricular ejection fraction (LVEF)1001928010027656NL-OMON34077Antoni van Leeuwenhoek Ziekenhuis160
Active, not recruiting
Not Applicable
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab - M06HERWHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic = 140 mmHg diastolic = 90 mmHg is acceptable at randomization. LVEF ? 50% assessed by multigated angiography (MUGA) or cardiac ultrasoundEUCTR2006-001707-11-NLKI-Av